Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.51 |
| ▸ | ATM | Q13315 | 12/20 | 0.51 |
| ▸ | PRKDC | P78527 | 6/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | SERPINA2 | P20848 | 1/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.49 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15105550 | 0.96 | ATR (0.50) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL14829726 | 0.96 | ATR (0.53) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL14829468 | 0.94 | ATR (0.52) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL15105545 | 0.93 | ATR (0.51) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL15105287 | 0.91 | ATR (0.51) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL15120091 | 0.91 | ATR (0.53) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL15120013 | 0.90 | ATR (0.54) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL14829356 | 0.88 | ATR (0.55) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL30275123 | 0.88 | ATR (0.67) | ATRATMPRKDCGSK3BJAK2 | |
| SCHEMBL2486945 | 0.88 | ATR (0.55) | ATRATMPRKDCGSK3BJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3878851-A1 | PROCESS FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-09-15 | — | — | EP | disclosed |
| US-10822331-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3608316-A1 | DEUTERATED DERIVATIVES OF AN INHIBITOR OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10435397-B2 | — | — | 2019-10-08 | — | — | US | disclosed |
| EP-2940017-B1 | Process for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMA (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-07-04 | — | — | US | disclosed |
| US-10208027-B2 | Processes for preparing ATR inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180244662-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2018-08-30 | — | — | US | disclosed |
| US-9862709-B2 | Processes for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-09 | — | — | US | disclosed |
| EP-2940017-A2 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150274710-A1 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-01 | — | — | US | disclosed |
| US-9035053-B2 | Processes for making compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2751097-A2 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130184292-A1 | Processes for Making Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013049726-A2 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822331-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | ATR 1/4885ATM 17/4885PRKDC 21/4885 |
| US-20130184292-A1 | Processes for Making Compounds Useful as Inhibitors of ATR Kinase | ATR, ATRIP, CHEK1 | ATR 1/4885ATM 22/4885PRKDC 12/4885 |
| US-20190202818-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | ATR, ATRIP, CHEK1 | ATR 1/4885ATM 19/4885PRKDC 20/4885 |
| US-10435397-B2 | — | ATR, ATRIP, TBK1 | ATR 1/4885ATM 35/4885PRKDC 22/4885 |
| US-20150274710-A1 | PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, ATRIP, CHEK1 | ATR 1/4885ATM 22/4885PRKDC 12/4885 |
| US-20180244662-A1 | PROCESSES FOR PREPARING ATR INHIBITORS | ATR, ATRIP, CHEK1 | ATR 1/4885ATM 19/4885PRKDC 20/4885 |
| US-10208027-B2 | Processes for preparing ATR inhibitors | ATR, ATRIP, CHEK1 | ATR 1/4885ATM 19/4885PRKDC 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.